Status:

TERMINATED

ANTERO-4: VIPUN Gastric Monitoring System in an Erythromycin Model

Lead Sponsor:

Prof Dr Jan Tack

Conditions:

Gastric Motility

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

It has been demonstrated that the VIPUN Gastric Monitoring System (GMS) can discriminate healthy physiological and pharmacologically-inhibited gastric motility, using a codeine-model in healthy adults...

Eligibility Criteria

Inclusion

  • Signed Informed Consent
  • Aged between and including 18 and 65 years
  • BMI between and including 18 and 30
  • Understand and able to read Dutch
  • In good health on the basis of medical history
  • Refrains from herbal, vitamin and other dietary supplements on the day of the visits

Exclusion

  • Dyspeptic symptoms (assessed with PAGI-SYM questionnaire)
  • Using any medication that might affect gastric function or visceral sensitivity
  • Known / suspected current use of illicit drugs
  • Known psychiatric or neurological illness
  • Any gastrointestinal surgery that could influence normal gastric function in the opinion of the investigator
  • History of heart or vascular diseases like irregular heartbeats, angina or heart attack
  • Nasopharyngeal surgery in the last 30 days
  • Suspected basal skull fracture or severe maxillofacial trauma
  • History of thermal or chemical injury to upper respiratory tract or esophagus
  • Current esophageal or nasopharyngeal obstruction
  • Known coagulopathy
  • Known esophageal varices
  • Pregnant or breastfeeding women
  • Have known side-effects/allergic reactions when taking erythromycin or other macrolide antibiotics (such as azithromycin, clarithromycin)
  • Kidney disease
  • Liver disease
  • Myasthenia gravis
  • QT prolongation (QT ≥400 ms) at the screening
  • Cardiac arrhythmia or heart failure
  • History of C. difficile infection
  • Family history of QT prolongation, sudden cardiac death or other heart problems
  • Recent vaccinations with live bacterial vaccines (such as typhoid vaccine)
  • Concomitant medication use

Key Trial Info

Start Date :

September 7 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 10 2020

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT04066231

Start Date

September 7 2019

End Date

March 10 2020

Last Update

August 12 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UZ Leuven

Leuven, Belgium, 3000